This is a prospective, single-center, open-label clinical study comparing the imaging performance of INR202 PET/CT versus 18F-FDG PET/CT in participants with advanced solid tumors.
Age ≥18 years.
ECOG performance status of 0 or 1.
Advanced solid tumors.
Adequate organ functions.
Unable to complete imaging examinations as required by the study protocol, in the investigator's judgement.
With a history of ≥2 malignancies within 5 years prior to administration of INR202, except for adequately treated non-metastatic thyroid cancer, basal cell carcinoma of the skin, superficial squamous cell carcinoma of the skin, or superficial bladder cancer.
Known hypersensitivity to the active ingredient of INR202 or any of its components.
Any medical condition or other situation that, in the investigator's judgement, may affect safety, compliance, or study outcomes.